BACKGROUND: Recipients of kidneys from living donors who subsequently develop end-stage renal disease (ESRD) also have higher graft failure, suggesting the 2 donor kidneys share risk factors that could inform recipient outcomes. Given that donor ESRD is rare, an earlier and more common postdonation outcome could serve as a surrogate to individualize counseling and management for recipients. Hypertension is a frequent event before donor ESRD; thus, early postdonation hypertension might indicate higher risk of graft failure. METHODS: We studied Scientific Registry of Transplant Recipients data to quantify the association between early postdonation hypertension and recipient graft failure using propensity score-weighted Cox proportional hazards regression. We also examined the association between postdonation systolic blood pressure and graft failure. RESULTS: Of 37 901 recipients, 2.4% had a donor who developed hypertension within 2 years postdonation. Controlling for donor and recipient characteristics, recipients whose donors developed hypertension had no higher risk for graft failure (adjusted hazard ratio [aHR] 1.03, 95% confidence interval [CI] 0.85-1.25, P = 0.72). This was consistent among subgroups of recipients at higher risk for adverse outcomes due to hyperfiltration: African American recipients (aHR 1.10, 95% CI 0.70-1.73, P = 0.68) and those with ESRD caused by hypertension (aHR 1.10, 95% CI 0.65-1.85, P = 0.73) or diabetes (aHR 0.80, 95% CI 0.56-1.13, P = 0.20). However, graft failure was associated with postdonation systolic blood pressure (per 10 mm Hg, aHR 1.05, 95% CI 1.03-1.08, P < 0.001). CONCLUSIONS: Although postdonation systolic blood pressure is associated with graft failure, the reported diagnosis of hypertension as determined by the requirement for blood pressure treatment early postdonation did not portend a higher risk of recipient graft failure in the same way as eventual postdonation ESRD.
BACKGROUND: Recipients of kidneys from living donors who subsequently develop end-stage renal disease (ESRD) also have higher graft failure, suggesting the 2 donor kidneys share risk factors that could inform recipient outcomes. Given that donor ESRD is rare, an earlier and more common postdonation outcome could serve as a surrogate to individualize counseling and management for recipients. Hypertension is a frequent event before donor ESRD; thus, early postdonation hypertension might indicate higher risk of graft failure. METHODS: We studied Scientific Registry of Transplant Recipients data to quantify the association between early postdonation hypertension and recipient graft failure using propensity score-weighted Cox proportional hazards regression. We also examined the association between postdonation systolic blood pressure and graft failure. RESULTS: Of 37 901 recipients, 2.4% had a donor who developed hypertension within 2 years postdonation. Controlling for donor and recipient characteristics, recipients whose donors developed hypertension had no higher risk for graft failure (adjusted hazard ratio [aHR] 1.03, 95% confidence interval [CI] 0.85-1.25, P = 0.72). This was consistent among subgroups of recipients at higher risk for adverse outcomes due to hyperfiltration: African American recipients (aHR 1.10, 95% CI 0.70-1.73, P = 0.68) and those with ESRD caused by hypertension (aHR 1.10, 95% CI 0.65-1.85, P = 0.73) or diabetes (aHR 0.80, 95% CI 0.56-1.13, P = 0.20). However, graft failure was associated with postdonation systolic blood pressure (per 10 mm Hg, aHR 1.05, 95% CI 1.03-1.08, P < 0.001). CONCLUSIONS: Although postdonation systolic blood pressure is associated with graft failure, the reported diagnosis of hypertension as determined by the requirement for blood pressure treatment early postdonation did not portend a higher risk of recipient graft failure in the same way as eventual postdonation ESRD.
Authors: Colin R Lenihan; Stephan Busque; Geraldine Derby; Kristina Blouch; Bryan D Myers; Jane C Tan Journal: J Clin Invest Date: 2015-02-17 Impact factor: 14.808
Authors: Rhiannon D Reed; Brittany A Shelton; Paul A MacLennan; Deirdre L Sawinski; Jayme E Locke Journal: Transplantation Date: 2018-01 Impact factor: 4.939
Authors: Geir Mjøen; Stein Hallan; Anders Hartmann; Aksel Foss; Karsten Midtvedt; Ole Øyen; Anna Reisæter; Per Pfeffer; Trond Jenssen; Torbjørn Leivestad; Pål-Dag Line; Magnus Øvrehus; Dag Olav Dale; Hege Pihlstrøm; Ingar Holme; Friedo W Dekker; Hallvard Holdaas Journal: Kidney Int Date: 2013-11-27 Impact factor: 10.612
Authors: Abimereki D Muzaale; Allan B Massie; Mei-Cheng Wang; Robert A Montgomery; Maureen A McBride; Jennifer L Wainright; Dorry L Segev Journal: JAMA Date: 2014-02-12 Impact factor: 56.272
Authors: Courtenay M Holscher; Sunjae Bae; Alvin G Thomas; Macey L Henderson; Christine E Haugen; Sandra R DiBrito; Abimereki D Muzaale; Jacqueline M Garonzik Wang; Allan B Massie; Krista L Lentine; Dorry L Segev Journal: Transplantation Date: 2019-06 Impact factor: 4.939